CoChat

GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms

Open access

The DOI matches its Crossref record; 204 of the 216 references it cites were found in a registry or an index.

Abstract

Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke. The cardiovascular benefits observed following GLP-1RA treatment could be secondary to improvements in glycemia, blood pressure, postprandial lipidemia, and inflammation. Yet, the GLP-1R is also expressed in the heart and vasculature, suggesting that GLP-1R agonism may impact the cardiovascular system. The emergence of GLP-1RAs combined with glucose-dependent insulinotropic polypeptide and glucagon receptor agonists has shown promising results as new weight loss medications. Dual-agonist and tri-agonist therapies have demonstrated superior outcomes in weight loss, lowered blood sugar and lipid levels, restoration of tissue function, and enhancement of overall substrate metabolism compared to using GLP-1R agonists alone. However, the precise mechanisms underlying their cardiovascular benefits remain to be fully elucidated. This review aims to summarize the findings from CVOTs of GLP-1RAs, explore the latest data on dual and tri-agonist therapies, and delve into potential mechanisms contributing to their cardioprotective effects. It also addresses current gaps in understanding and areas for further research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/joe-24-0046

Cites

204 of 204 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cardiovascular benefits of GLP-1RA, dual, or triple agonists. (A) Distribution of Glp1r or GLP1R (in black), Gipr or GIPR (in blue), and Gcgr or GCGR (in green) mRNA in the heart of humans and mice. (B) Mechanisms of action by which GLP-1RA (black), dual (blue), or triple agonists (green) improve cardiovascular outcomes. GLP-1RA, glucagon-like peptide 1 receptor agonist; GIPR, glucose-dependent insulinotropic peptide receptor; GCGR, glucagon receptor; TG, triglycerides; VLDL, very low-density lipoproteins; AMPK, 5' adenosine monophosphate-activated protein kinase.
Figure 1 Cardiovascular benefits of GLP-1RA, dual, or triple agonists. (A) Distribution of Glp1r or GLP1R (in black), Gipr or GIPR (in blue), and Gcgr or GCGR (in green) mRNA in the heart of humans and mice. (B) Mechanisms of action by which GLP-1RA (black), dual (blue), or triple agonists (green) improve cardiovascular outcomes. GLP-1RA, glucagon-like peptide 1 receptor agonist; GIPR, glucose-dependent insulinotropic peptide receptor; GCGR, glucagon receptor; TG, triglycerides; VLDL, very low-density lipoproteins; AMPK, 5' adenosine monophosphate-activated protein kinase.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 61

Metadata

Authors
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E.
Affiliations
  • University of Ottawa (CA)
  • Ottawa Heart Institute (CA)
Venue
Journal of Endocrinology
Published
2024-08-15
Volume
263
Issue
1
ISSN
  • 0022-0795 (ISSN-L)
  • 1479-6805
OpenAlex
W4401614784
Cited by
51
References
216
Citations by year
2026: 36 · 2025: 15
FWCI
2.99
Type
journal article
Language
en
Open access
Locations
  • Journal of Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, cardiovascular risk, cardioprotection, type 2 diabetes, obesity, cardiovascular outcome trials, GIP/GLP-1 dual agonist, anti-obesity drugs, myocardial infarction, stroke, glycemia, blood pressure, postprandial lipemia, inflammation
MeSH terms
Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.